- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04324593
Healthy Volunteer Study to Evaluate the Impact of Various Common Interventions on Venous Pressure Signal Captured by PIVA
Healthy Volunteer Study to Evaluate the Impact of Various Common Interventions on Venous Pressure Signal Captured by Peripheral Intravenous Analysis (PIVA) Technology
Non-invasive sensors have been used in research in the United States (US) to aid in the assessment of a subject's heart rate (HR), respiratory rate (RR) and fluid volume status. This estimate and its trended value over time, when used along with clinical signs and symptoms and other subject test results, can aid in the process of reaching a diagnosis and formulating a therapeutic plan when abnormalities of volume status, or RR are suspected.
Non-invasive sensors like the Peripheral IntraVenous Analysis (PIVA) sensor under development by Baxter and the Deltran blood pressure (BP) transducer, capture waveforms created by physiological mechanisms such as blood flow and breathing. An algorithm is then applied to the captured waveform to give clinicians an idea of hemodynamic (volume) status, and RR.
In this study, the functional robustness (e.g., subjects sitting, elevated leg positions, etc.) of the PIVA algorithm/technology will be demonstrated by evaluating the impact of various common interventions on the venous pressure signal. All subjects will undergo 33 interventions expected to take approximately 4 - 6 hours.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Florida
-
Miami, Florida, Verenigde Staten, 33126
- Baxter Investigational SIte
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Has reviewed, understood and signed an informed consent.
- Age between 18-55 years.
- Body mass index between 18.5-35 kg/m2 with a minimum weight of 45 kg.
- Willing and able to comply with study procedures and duration.
- Subjects wearing any type of nail polish and/or acrylic nails must be willing to remove them prior to admission.
Exclusion Criteria:
- Female subjects who are pregnant.
- Subjects who are currently participating in, or have within the past 30 days participated in, another interventional clinical study or have used an investigational device or drug within the past 30 days.
Subjects with known respiratory conditions including but not limited to:
- uncontrolled / severe asthma
- flu / influenza
- pneumonia / bronchitis
- shortness of breath / respiratory distress
- respiratory or lung surgery
- emphysema, chronic obstructive pulmonary disease, lung disease
- any other health condition that the Principal Investigator thinks can affect respiratory health
Subjects with self-reported heart or cardiovascular conditions including but not limited to:
- hypertension
- history of cardiovascular surgery
- chest pain (angina)
- heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia
- previous heart attack
- blocked artery
- unexplained shortness of breath
- congestive heart failure
- history of stroke
- transient ischemic attack
- carotid artery disease
- myocardial ischemia
- myocardial infarction
- restrictive or constrictive cardiomyopathy
- congenital heart disease other than patent foramen ovale, repaired atrial or ventricular septal defect
- any type of cardiac valve disease
- history of cardiac arrhythmias
Self-reported health conditions as identified in the Health Assessment Form
- diabetes
- uncontrolled thyroid disease
- kidney disease / chronic renal impairment
- history of seizures (except childhood febrile seizures)
- epilepsy
- history of unexplained syncope
- history of migraine attacks in the last 3 months
- head injury within the last 2 months
- cancer / chemotherapy
- other known health condition should be considered upon disclosure in health assessment form
- history of substance abuse or addiction to alcohol and or drugs within the last 12 months
Subjects with self-reported bleeding disorders including but not limited to:
- hemophilia
- von Willebrand disease
- history of blood clots
- history of bleeding problems
- bruises easily with everyday activities
- Subjects taking prescription blood thinners (like aspirin, clopidogrel, dipyridamole, or ticlopidine).
- Subjects may be excluded at the discretion of the Investigator.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Toestel Haalbaarheid
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: IV line with an attached Deltran BP transducer
After device setup, subjects will be guided through a series of manipulations of the IV set while waveforms, pulse rate (PR), respiratory rate (RR) are collected at the start and stop of each test.
At the end of the study, the PIVA algorithm will then be applied to the waveforms and calculated values will be compared with those from bedside monitors to understand the effect of common manipulations on the waveforms and determine most optimal conditions for capturing RR and PR through peripheral IV analysis.
|
An IV line with an attached Deltran BP transducer will be used together with LabChart software to record venous waveforms during various interventions.
These waveforms will be processed using the PIVA algorithm and the calculated values will be compared to those from Nellcor respiratory monitor, Capnograph and cardiac telemetry monitoring.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Signal Quality Index (SQI) Score by Supine, Sitting, Standing Body Positions
Tijdsspanne: End of interventions #15 (supine for 5 minutes), #17 (sitting for 5 minutes), and #19 (standing for 5 minutes)
|
Ranking of subject body positions (supine, sitting, standing) based upon their impact on the venous waveform signal, from best to worst, based on the PIVA algorithm-derived SQI.
Score on the scale include 0=no signal, 1=poor signal, 2=good signal.
The highest percentage of time with good signal quality will be the best ranked position, and the lowest percentage of time with good signal quality will be the worst ranked position.
|
End of interventions #15 (supine for 5 minutes), #17 (sitting for 5 minutes), and #19 (standing for 5 minutes)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Agreement between PIVA algorithm-derived RR and RR measured with Capnography at Baseline
Tijdsspanne: End of 10 minute baseline
|
The difference of the PIVA algorithm-derived outcomes to their comparators (Capnography) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum.
The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints.
Capnography is the monitoring of the concentration or partial pressure of carbon dioxide in the respiratory gases.
|
End of 10 minute baseline
|
Agreement between PIVA algorithm-derived RR and RR measured with Nellcor bedside monitor at Baseline
Tijdsspanne: End of 10 minute baseline
|
The difference of the PIVA algorithm-derived outcomes to their comparators (Nellcor) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum.
The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints.
|
End of 10 minute baseline
|
Agreement between PIVA algorithm-derived RR and RR measured with manual counting
Tijdsspanne: End of 10 minute baseline
|
The manual count value will be an average of the 2 minutes then the count is taken over.
The difference of the PIVA algorithm-derived outcomes to their comparators (manual) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum.
The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints.
|
End of 10 minute baseline
|
Agreement between PIVA algorithm derived PR and PR measured with Nellcor bedside monitor at Baseline
Tijdsspanne: End of 10 minute baseline
|
The difference of the PIVA algorithm-derived outcomes to their comparators (Nellcor) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum.
The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints.
|
End of 10 minute baseline
|
Change in PIVA algorithm derived volume index between supine and passive leg raising positions
Tijdsspanne: End of Interventions #15 (supine for 5 minutes) and #18 (passive leg raise for 5 minutes)
|
The change in PIVA algorithm-derived volume index for a change in positions will be summarized descriptively by n, mean, median, minimum, and maximum.
|
End of Interventions #15 (supine for 5 minutes) and #18 (passive leg raise for 5 minutes)
|
Change in PIVA algorithm derived volume index between supine and standing positions
Tijdsspanne: End of interventions #15 (supine for 5 minutes) and #19 (standing for 5 minutes)
|
The change in PIVA algorithm-derived volume index for a change in positions will be summarized descriptively by n, mean, median, minimum, and maximum.
|
End of interventions #15 (supine for 5 minutes) and #19 (standing for 5 minutes)
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- BXU544319
- Pro00041143 (Andere identificatie: Advarra)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Gezonde vrijwilligers
-
University of LeicesterNational Institute for Health Research, United KingdomVoltooidPatiënten met hartfalen en behouden ejectiefractie - HFpEF | Patiënten met hartfalen met verminderde ejectiefractie - HFrEF | Healthy Controls Group - Leeftijd en geslacht afgestemd
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesBeëindigdZiekte van Parkinson | Healthy Controls Group - Leeftijd en geslacht afgestemdFrankrijk